Source:

ter Laak
MA
,
Temmink
AH
,
Koeken
A
, et al
.
Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity
.
Pediatr Neurol
.
2010
;
43
(
3
):
159
162
; doi:
https://doi.org/10.1016/j.pediatrneurol.2010.04.004

Investigators from the Netherlands performed a study to determine whether the genotypic pattern of cytochrome P450 pathway activity has a characteristic pattern associated with delayed response and adverse effects from atomoxetine in a series of children with attention deficit hyperactivity disorder (ADHD). Atomoxetine is a nonstimulant medication used to treat ADHD which is metabolized mainly through the cytochrome P450 2D6 (CYP2D6) enzyme pathway. Polymorphisms of this pathway are common in Caucasians and can result in a reduced ability to metabolize atomoxetine, leading to variability in efficacy and tolerability.

Of 100 patients being treated with atomoxetine for ADHD, 10 took longer than 9 weeks to achieve therapeutic effects and...

You do not currently have access to this content.